Stock Evaluator: Becton, Dickinson and Company (BDX)

588 followers

Becton, Dickinson and Company BDX

$165.62 0.17 0.10%
July 31, 2026 4:00:02 PM EST November 10, 2021 Volume: 2,024,693
After Hours: $120.37   0.15  |  0.12% November 10, 2021 7:59 PM EST Volume: 72,713
USD NYSE | DELAYED PRICE
SECTOR INDUSTRY
Health Care Health Care Equipment & Supplies

A+ Stock Grade Summary:

VALUE:
GROWTH:
MOMENTUM:
EPS REVISIONS:
QUALITY:
COMPANY SUMMARY
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. It operates through Medical Essentials, Connected Care, BioPharma Systems, Interventional and Life Sciences segments. It provides peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular access technology, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication safety and infusion therapy delivery systems, medication compounding workflow system, automated medication dispensing and supply management systems, informatics and analytics and pharmacy automation system, and medication inventory optimization and tracking system; hemodynamic monitoring system; and prefillable drug delivery systems. It also offers specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, and microorganism identification and drug susceptibility, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent system, and solution for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. It provides hernia and soft tissue repair, biological and bioresorbable graft, biosurgery, and other surgical products; surgical infection prevention, peripheral intervention, and urology and critical care products. The company has a strategic collaboration with ChemoGLO for the advancement of hazardous drug contamination testing in health care settings to improve the safety of health care workers. The company was founded in 1897 and is headquartered in Franklin Lakes, New Jersey.

Commentary & Analysis


Financial Summary

Share Statistics BDX Industry
Median
Percentile
(All Stocks)
Market Cap (Mil) $45,635.0 $337.2 93%
Shares Out (Mil) 280.6 41.9 82%
Institutional Ownership 99.8% 77.8% 94%
Float (Mil) 274.7 34.7 79%
Beta 0.29 0.85 17%
Avg Daily Volume (000s) 1,716 278 79%
Price Change
(52-week)
(8.8%) 58.7% 38%
Growth BDX Industry
Median
Percentile
(All Stocks)
Sales (5yr) 6.3% 11.8% 42%
Net Income (5yr) 13.9% (5.8%) 61%
EPS (5yr) 16.4% 11.4% 60
Dividends (5yr) 5.7% 0.0% 97%
Cash Flow (5yr) (19.3%) (16.3%) 35%
Estimates Qtrly Current
Fiscal
Year
Next
Fiscal
Year
# of Estimates 12 14 14
Current EPS $3.138 $12.560 $13.460
Month Ago EPS $3.131 $12.545 $13.393
# Rev Up 1 0 1
# Rev Down 0 1 0
Three Months Ago EPS $3.086 $12.476 $13.504
Year/Year Chg (2,477%) 115.8% 146.8%
Financials BDX Industry
Median
Percentile
(All Stocks)
Sales (TTM) (Mil) $22,227 $152 92%
Net Income (TTM) (Mil) $1,139 ($10) 88%
EPS (TTM) $3.996 ($0.500) 83%
Operating Cash Flow (TTM) (Mil) $3,828 ($2) 93%
Net Cash Flow (TTM) (Mil) na $1 na
Long-Term Debt (Q1) (Mil) $14,706 $22 94%
Enterprise Value (Q1) (Mil) $57,356 $304 93%
Valuation BDX Industry
Median
Percentile
(All Stocks)
P/B 1.89 2.80 49%
P/E 28.8 31.1 66%
Dividend Yield 2.5% 0.0% 80%
PEG (5yr hist) 0.6 1.9 30%
Ratios BDX Industry
Median
Percentile
(All Stocks)
Gross Margin 47.1% 59.1% 59%
Net Margin 5.1% (7.3%) 49%
ROA 2.2% (13.7%) 57%
ROE 4.6% (15.8%) 43%
Liabilities to Assets 52.5% 44.7% 45%
F-Score 7 4 84%

Becton, Dickinson and Company did not pass any screens on 7/31/2026.

Price and market data provided by QuoteMedia and delayed a minimum of 15 minutes unless otherwise indicated. Fundamental data provided by AAII's Stock Investor Pro and S&P Global Market Intelligence and are updated through the previous trading day.

Ⓒ 2026 American Association of Individual Investors